期刊文献+
共找到125篇文章
< 1 2 7 >
每页显示 20 50 100
SARS-CoV-2 B.1.1.7核衣壳蛋白突变与宿主天然免疫应答及COVID-19临床状态的相关性
1
作者 何先珍 付亚男 +4 位作者 尤婉玲 耿澳华 孙晓光 曾凤 刘龙 《天津医药》 2025年第12期1240-1245,共6页
目的 阐明新型冠状病毒(SARS-CoV-2) B.1.1.7变异株核衣壳蛋白(N蛋白)特异性突变体(N_(D3L)、N_(M234I)和N_(R203K-G204R-T205I))与新型冠状病毒感染(COVID-19)患者临床状态的相关性,揭示其对N蛋白液-液相分离(LLPS)现象和宿主天然免疫... 目的 阐明新型冠状病毒(SARS-CoV-2) B.1.1.7变异株核衣壳蛋白(N蛋白)特异性突变体(N_(D3L)、N_(M234I)和N_(R203K-G204R-T205I))与新型冠状病毒感染(COVID-19)患者临床状态的相关性,揭示其对N蛋白液-液相分离(LLPS)现象和宿主天然免疫应答的影响。方法 基于全球共享流感数据倡议组织(GISAID)数据库的SARS-CoV-2 B.1.1.7谱系全基因组测序数据,筛选与轻/重症临床表型显著相关的非同义突变位点。针对高频N蛋白突变体,采用双荧光素酶报告系统定量检测干扰素(IFN)-β启动子转录活性;qPCR检测IFN-β、白细胞介素(IL)-6、肿瘤坏死因子(TNF)-αmRNA表达水平;通过激光共聚焦显微观察LLPS特征。蛋白印迹检测宿主线粒体抗病毒信号蛋白(MAVS)的泛素化修饰状态。结果 共鉴定出17 640个非同义突变位点,其中突变频率>1%且有65个与轻症相关,20个与重症相关。与重症相关的N蛋白突变位点为D3L、M234I、R203K-G204R-T205I。N蛋白及N_(M234I)、N_(R203K-G204R-T205I)突变体均可抑制IFN-β的启动子活性(P<0.05)。相较于野生型N,N_(R203K-G204R-T205I)突变体可显著降低IFN-β、IL-6和TNF-α mRNA水平(P<0.05),同时可通过分散LLPS凝聚点的形成而改变相分离状态。但N突变体不影响宿主MAVS的泛素化修饰。结论 SARS-CoV-2 B.1.1.7变异株N蛋白突变体可通过改变LLPS状态抑制天然免疫应答,进而影响COVID-19患者的临床预后。 展开更多
关键词 新型冠状病毒 冠状病毒核壳蛋白质类 干扰素Β 临床状态 b.1.1.7谱系 液-液相分离
暂未订购
Clinical and laboratory features of COVID-19 patients infected with SARS-CoV-2 variant B.1.1.7 versus those infected with other SARS-CoV-2 strains:A retrospective observational study
2
作者 Zeynep Ergenc Hasan Ergenc +3 位作者 AhmetÖztürk Gülsüm Kaya Özlem Karaca Ocak Özgürİnce 《Journal of Acute Disease》 2022年第6期236-242,共7页
Objective:To investigate the clinical symptoms of coronavirus disease 2019(COVID-19)patients with and without B.1.1.7 mutation.Methods:This retrospective observational study included COVID-19 patients who were divided... Objective:To investigate the clinical symptoms of coronavirus disease 2019(COVID-19)patients with and without B.1.1.7 mutation.Methods:This retrospective observational study included COVID-19 patients who were divided into two groups,the mutation and the non-mutation group.Demographics characteristics,clinical characteristics,laboratory parameters,and mortality rates were recorded and compared between the two groups.Results:A total of 196 patients were included in the study.The relationship between the mutant virus status and sex,age,comorbidity,survival status,and disease severity was not significant(P>0.05).No significant differences were found in duration of hospitalization between the mutation and the non-mutation group(P>0.05).However,there was a statistically significant difference between patients with and without mutant viruses in hemoglobin,mean platelet volume,procalcitonin,low density lipoprotein,iron-binding capacity,potassium,calcium,C-reactive protein,folate,creatine kinase myocardial band,D-dimer,and international normalized ratio(P<0.05).Conclusions:No significant difference is found in mortality rate,disease severity or duration of hospitalization between the patients with and without variant B.1.1.7.Careful monitoring of COVID-19 patients is required for all variants. 展开更多
关键词 COVID-19 b.1.1.7 variant Mutation Clinical parameters Laboratory parameters
暂未订购
银杏内酯B通过激活ITP小鼠mTOR信号通路调节lncRNA PVT1促进Treg/Th17免疫平衡而抑制炎症反应的机制研究
3
作者 杨亚丽 雷蕊 +2 位作者 张宝君 张丙寅 王金龙 《现代检验医学杂志》 2026年第1期35-40,45,共7页
目的探讨银杏内酯B通过激活免疫性血小板减少症(ITP)哺乳动物雷帕霉素靶蛋白(mTOR)信号通路调节长链非编码RNA人浆细胞瘤转化迁移基因1(lncRNA PVT1)促进调节性T淋巴细胞/辅助性T淋巴细胞17(Treg/Th17)免疫平衡而抑制炎症反应的机制。... 目的探讨银杏内酯B通过激活免疫性血小板减少症(ITP)哺乳动物雷帕霉素靶蛋白(mTOR)信号通路调节长链非编码RNA人浆细胞瘤转化迁移基因1(lncRNA PVT1)促进调节性T淋巴细胞/辅助性T淋巴细胞17(Treg/Th17)免疫平衡而抑制炎症反应的机制。方法选用80只雄性SD小鼠,采用腹腔注射抗小鼠血小板血清方法建立模型,随机分为正常组、模型组、低剂量组、高剂量组,每组20只,连续给药14天。实时荧光定量PCR(qRT-PCR)检测血清lncRNA PVT1表达,流式细胞仪检测Treg/Th17细胞,Western Blot检测磷脂酰肌醇-3-激酶(PI3K)、Akt、mTOR蛋白表达。检测血清白细胞介素-4(IL-4)、干扰素-γ(IFN-γ)和全血血小板计数(PLT)。结果与正常组比较,模型组小鼠血清lncRNA PVT1、Th17、IFN-γ升高,Treg、Treg/Th17、PI3K、Akt、mTOR蛋白、IL-4、PLT降低,差异具有统计学意义(t=2.510~54.899,均P<0.05);与模型组比较,低剂量组、高剂量组lncRNA PVT1(1.99±0.14、1.25±0.11 vs 2.39±0.15)、Th17(1.76%±0.32%、0.87%±0.04%vs 5.28%±1.21%)、IFN-γ(7.65±0.28pg/ml、6.84±0.33pg/ml vs 8.45±0.36 pg/ml)均降低(t_(低剂量组)=8.718、8.782、3.292,t_(高剂量组)=27.408、9.789、6.542),Treg(3.46%±0.43%、4.77%±0.51%vs 2.41%±0.44%)、Treg/Th17(1.98±0.16、4.24±1.02 vs 0.45±0.05)、PI3K(0.88±0.08、1.22±0.21 vs 0.45±0.05)、Akt(0.66±0.07、1.11±0.11 vs 0.21±0.02)、mTOR蛋白(0.70±0.08、1.21±0.13 vs 0.45±0.06)、IL-4(12.28±1.28pg/ml、13.08±1.01pg/ml vs 11.45±1.05pg/ml)、PLT[(526.99±50.34)×10^(9)/L、(880.37±52.78)×10^(9)/L vs(218.58±50.35)×10^(9)/L]均升高(t_(低剂量组)=4.943~27.643,t_(高剂量组)=7.766~40.818),差异具有统计学意义(均P<0.05)。与低剂量组比较,高剂量组lncRNA PVT1、Th17、IFN-γ降低,Treg、Treg/Th17、PI3K、Akt、mTOR蛋白、IL-4、PLT升高,差异具有统计学意义(t=2.411~21.667,均P<0.05)。结论银杏内酯B可通过激活mTOR信号通路,调节lncRNA PVT1促进Treg/Th17免疫平衡,抑制ITP小鼠炎症反应,提升血小板数量。 展开更多
关键词 银杏内酯b 免疫性血小板减少症 哺乳动物雷帕霉素靶蛋白 长链非编码RNA人浆细胞瘤转化迁移基因1 调节性T细胞/辅助性T细胞17
暂未订购
清热化湿抗毒法治疗SARS-CoV-2 B.1.1.7毒株感染1例 被引量:1
4
作者 伍建光 赖俊宇 +1 位作者 张元兵 刘良徛 《中医杂志》 CSCD 北大核心 2022年第10期998-1000,共3页
SARS-CoV-2 B.1.1.7毒株是新型冠状病毒(COVID-19)的变种。报告1例普通型SARS-CoV-2B.1.1.7毒株感染病例,在西医治疗的同时采用中医清热化湿抗毒法治疗后痊愈出院。提示病毒虽然发生变异,但病机仍以湿热多见,病位以肺脾为主,只要谨守病... SARS-CoV-2 B.1.1.7毒株是新型冠状病毒(COVID-19)的变种。报告1例普通型SARS-CoV-2B.1.1.7毒株感染病例,在西医治疗的同时采用中医清热化湿抗毒法治疗后痊愈出院。提示病毒虽然发生变异,但病机仍以湿热多见,病位以肺脾为主,只要谨守病机,采用清热化湿抗毒法,在临床应用的过程中根据患者病情变化而随证加减,仍可获得良好疗效。 展开更多
关键词 新型冠状病毒 SARS-CoV-2 b.1.1.7毒株 瘟疫 清热化湿抗毒法 病例报告
原文传递
EphA3受体截短突变体variant b在前列腺癌细胞中的分泌表达
5
作者 钱晓龙 庞博 +4 位作者 施庆国 武瑞琴 俞岚 李山虎 周建光 《生物技术通讯》 CAS 2010年第1期27-31,共5页
目的:验证EphA3受体截短突变体variant b是否是一种分泌蛋白,并探索其内源分泌的特点,在细胞水平看其是否有作为前列腺癌血清标志物的潜质。方法:构建EphA3 variant b真核表达载体,应用标签抗体、特异性抗体和Western印迹检测前列腺癌... 目的:验证EphA3受体截短突变体variant b是否是一种分泌蛋白,并探索其内源分泌的特点,在细胞水平看其是否有作为前列腺癌血清标志物的潜质。方法:构建EphA3 variant b真核表达载体,应用标签抗体、特异性抗体和Western印迹检测前列腺癌细胞培养液中EphA3 variant b的表达,用RT-PCR方法分析EphA3 variant b在8种细胞系中的表达谱和对雄激素刺激的应答。结果:验证了EphA3 variant b是一种分泌蛋白,在雄激素受体阳性的前列腺癌细胞系中特异性表达,雄激素以剂量依赖方式诱导EphA3 variant b表达。结论:EphA3 variant b是一种分泌蛋白,其表达与雄激素受体信号通路相关,有作为前列腺癌血清标志物的潜质。 展开更多
关键词 前列腺癌 血清标志物 分泌蛋白 EphA3截短突变体variant b
在线阅读 下载PDF
新型冠状病毒B.1.1.7变异株特异性数字PCR定量方法研究 被引量:1
6
作者 王霞 郭若晖 董莲华 《计量学报》 CSCD 北大核心 2023年第5期826-832,共7页
由于世界卫生组织(WHO)将B.1.1.7(Alpha)列为“关切的变异株”,因此对其建立特异性的高灵敏数字PCR方法尤为重要。该方法需首先根据该变异株刺突蛋白的H69/V70缺失、P681H和A570D 3个特异突变位点设计引物探针,确定3个方法的线性范围和... 由于世界卫生组织(WHO)将B.1.1.7(Alpha)列为“关切的变异株”,因此对其建立特异性的高灵敏数字PCR方法尤为重要。该方法需首先根据该变异株刺突蛋白的H69/V70缺失、P681H和A570D 3个特异突变位点设计引物探针,确定3个方法的线性范围和定量限;随后再用其他4个“关切的变异株”验证该方法的特异性,并用不同数字PCR平台和不同方法进行定量准确性的比较;最终,结果表明建立的数字PCR方法准确可靠,可用于B.1.1.7变异株的定量检测。 展开更多
关键词 计量学 新型冠状病毒 b.1.1.7变异株 定量检测 数字PCR
在线阅读 下载PDF
结节型间变型弥漫大B细胞淋巴瘤1例
7
作者 赵敏 李丹 《临床与实验病理学杂志》 北大核心 2025年第2期278-280,共3页
间变型弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)是一种罕见的非特指型DLBCL,组织形态学常为窦性或者弥漫生长。该文报道1例,其左侧腋窝淋巴结具有大量多形性的中心母细胞样伴间变特征的细胞和HRS样细胞呈结节状或滤泡... 间变型弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)是一种罕见的非特指型DLBCL,组织形态学常为窦性或者弥漫生长。该文报道1例,其左侧腋窝淋巴结具有大量多形性的中心母细胞样伴间变特征的细胞和HRS样细胞呈结节状或滤泡生发中心样生长,符合DLBCL,非特殊类型,间变型。结合相关文献探讨其临床病理学及分子遗传学特征,以提高临床和病理医师对该肿瘤的认识。 展开更多
关键词 弥漫大b细胞淋巴瘤 结节型 间变型 病例报道
暂未订购
Hepatitis B virus pre-S/S variants in liver diseases 被引量:16
8
作者 Bing-Fang Chen 《World Journal of Gastroenterology》 SCIE CAS 2018年第14期1507-1520,共14页
Chronic hepatitis B is a global health problem. The clinical outcomes of chronic hepatitis B infection include asymptomatic carrier state, chronic hepatitis(CH), liver cirrhosis(LC), and hepatocellular carcinoma(HCC).... Chronic hepatitis B is a global health problem. The clinical outcomes of chronic hepatitis B infection include asymptomatic carrier state, chronic hepatitis(CH), liver cirrhosis(LC), and hepatocellular carcinoma(HCC). Because of the spontaneous error rate inherent to viral reverse transcriptase, the hepatitis B virus(HBV) genome evolves during the course of infection under the antiviral pressure of host immunity. The clinical significance of pre-S/S variants has become increasingly recognized in patients with chronic HBV infection. Pre-S/S variants are often identified in hepatitis B carriers with CH, LC, and HCC, which suggests that these naturally occurring pre-S/S variants may contribute to the development of progressive liver damage and hepatocarcinogenesis. This paper reviews the function of the pre-S/S region along with recent findings related to the role of pre-S/S variants in liver diseases. According to the mutation type, five pre-S/S variants have been identified: pre-S deletion, pre-S point mutation, pre-S1 splice variant, C-terminus S point mutation, and pre-S/S nonsense mutation. Their associations with HBV genotype and the possible pathogenesis of pre-S/S variants are discussed. Different pre-S/S variants cause liver diseases through different mechanisms. Most cause the intracellular retention of HBV envelope proteins and induction of endoplasmic reticulum stress, which results in liver diseases. Pre-S/S variants should be routinely determined in HBV carriers to help identify individuals who may be at a high risk of less favorable liver disease progression. Additional investigations are required to explore the molecular mechanisms of the pre-S/S variants involved in the pathogenesis of each stage of liver disease. 展开更多
关键词 HEPATITIS b virus pre-S/S mutant pre-S DELETION SPLICE variant spPS1 chronic HEPATITIS liver cirrhosis HEPATOCELLULAR carcinoma
暂未订购
Omicron variant (B.1.1.529) of SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance 被引量:65
9
作者 Shi-Yan Ren Wen-Biao Wang +1 位作者 Rong-Ding Gao Ai-Mei Zhou 《World Journal of Clinical Cases》 SCIE 2022年第1期1-11,共11页
The appearance of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)variant Omicron(B.1.1.529)has caused panic responses around the world because of its high transmission rate and number of mutations.This rev... The appearance of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)variant Omicron(B.1.1.529)has caused panic responses around the world because of its high transmission rate and number of mutations.This review summarizes the highly mutated regions,the essential infectivity,transmission,vaccine breakthrough and antibody resistance of the Omicron variant of SARSCoV-2.The Omicron is highly transmissible and is spreading faster than any previous variant,but may cause less severe symptoms than previous variants.The Omicron is able to escape the immune system’s defenses and coronavirus disease 2019 vaccines are less effective against the Omicron variant.Early careful preventive steps including vaccination will always be key for the suppression of the Omicron variant. 展开更多
关键词 COVID-19 Omicron variant b.1.1.529 SARS-CoV-2 Infectivity TRANSMISSION variant of concern GENOTYPING RT-PCR
暂未订购
HBeAg negative variants and their role in the natural history of chronic hepatitis B virus infection 被引量:24
10
作者 Alexra Alexopoulou Peter Karayiannis 《World Journal of Gastroenterology》 SCIE CAS 2014年第24期7644-7652,共9页
Molecular virology methods including polymerase chain reaction, cloning and sequencing have revolutionised our understanding of viral genome variation. In the case of hepatitis B virus (HBV), sequencing studies have i... Molecular virology methods including polymerase chain reaction, cloning and sequencing have revolutionised our understanding of viral genome variation. In the case of hepatitis B virus (HBV), sequencing studies have identified a number of virus variants normally found during the natural course of chronic infection. The appearance of the precore stop codon (with G-for-A substitution at position 1896) and basal core promoter (BCP) (with A-for-T and G-for-A, at positions 1762 and 1764, respectively) variants which reduce or abrogate hepatitis B e antigen (HBeAg) production, heralds the initiation of the seroconversion phase from HBeAg to anti-HBe positivity. The gradual removal of the tolerogenic effect of HBeAg leads to the awakening of the immune response (immune clearance phase). Most patients after HBeAg seroconversion become &#x0201c;inactive HBsAg carriers&#x0201d;. However during the course of infection precore and/or BCP variants may emerge and be selected leading to HBeAg negative chronic hepatitis B (CHB) with high viremia levels (reactivation phase). The prevalence of HBeAg negative CHB has been increasing over the last few decades and has become the commonest type of HBV infection in many countries of the world. This probably reflects the aging of existing HBV carriers and the effective prevention measures restricting new HBV infections. Frequent acute exacerbations accompanied by high viral replication, elevated alanine aminotransferase levels and histological activity are a common feature of HBeAg negative CHB leading to cirrhosis much faster than in HBeAg positive CHB patients. 展开更多
关键词 Precore stop codon variants basal core promoter variants hepatitis b e antigen negative chronic hepatitis b Re-activation Hepatitis b virus-DNA replication
暂未订购
PCR restriction fragment length polymorphism in detection of YMDD variants of viral polymerase in hepatitis B virus patients treated with lamivudine 被引量:7
11
《Hepatobiliary & Pancreatic Diseases International》 SCIE CAS 2002年第2期232-237,共6页
Objective: To analyse the emergence of YMDD motif(tyrosine-methionine-aspartate-aspartate) variants inpatients with hepatitis B treated with lamivudine.Methods: The amino acid substitution from methio-nine or isoleuci... Objective: To analyse the emergence of YMDD motif(tyrosine-methionine-aspartate-aspartate) variants inpatients with hepatitis B treated with lamivudine.Methods: The amino acid substitution from methio-nine or isoleucine at the YMDD motif at the HBVpolymerase gene is a main mutation resistant to lami-vudine treatment. Generated from a fragment of do-main C of the polymerase gene, patients HBV DNA,which had been positive previously became positive a-gain ever since it had been negative during lamivudi-ne therapy. Variants were detected by cleavage of theproducts of the three PCRs with following enzymes:FokI, SspI, Alw441. The results of PCR-RELP wereanalysed by 8. 4% polypropylene acidemide gel elec-trophoresis. PCR-RFLP assay was compared to di-rect sequencing.Results: HBV DNA was positive again in 33 patientsand positive for one year in 2 patients. YMDD vari-ants were detected in serum 14 of 35 patients, YIDDvariants in 4, YVDD variants in 6, and YI/MDD va-riants in 1; all were in concordance with the resultsof direct sequencing. The samples of other 3 patientsshowed YI/VDD mutations, as shown by direct se-quencing. The results of PCR-RFLP assay of themixed sera of YIDD and YVDD variants were similarto those sera of YI/VDD variants.Conclusion: PCR-RFLP is suitable for rapid detec-tion of YMDD variants of viral polymerase in hepati-tis B virus patients treated with lamivudine. 展开更多
关键词 YMDD variantS PCR-RFLR hepatitis b virus LAMIVUDINE POLYMERASE gene
暂未订购
Induction of endoplasmic reticulum-derived oxidative stress by an occult infection related S surface antigen variant 被引量:5
12
作者 In-Kyung Lee Seoung-Ae Lee +2 位作者 Hong Kim You-Sub Won Bum-Joon Kim 《World Journal of Gastroenterology》 SCIE CAS 2015年第22期6872-6883,共12页
AIM: To investigate the mechanism of endoplasmic reticulum(ER) stress induction by an occult infection related hepatitis B virus S surface antigen(HBsAg)variant.METHODS: We used an HBsAg variant with lower secretion c... AIM: To investigate the mechanism of endoplasmic reticulum(ER) stress induction by an occult infection related hepatitis B virus S surface antigen(HBsAg)variant.METHODS: We used an HBsAg variant with lower secretion capacity, which was a KD variant from a Korean subject who was occultly infected with the genotype C. We compared the expression profiles of ER stress-related proteins between HuH-7 cells transfected with HBsAg plasmids of a wild-type and a KD variant using Western blot.RESULTS: Confocal microscopy indicated that the KD variant had higher levels of co-localization with ER than the wild-type HBsAg. The KD variant upregulated ER stress-related proteins and induced reactive oxygen species(ROS) compared to the wildtype via an increase in calcium. The KD variant also down-regulated anti-oxidant proteins(HO-1, catalase and SOD) compared to the wild-type, which indicates positive amplification loops of the ER-ROS axis. The KD variant also induced apoptotic cell death via the upregulation of caspase proteins(caspase 6, 9 and 12).Furthermore, the KD variant induced a higher level of nitric oxide than wild-type HBsAg via the up-regulation of the iNOS protein.CONCLUSION: Our data indicate that occult infection related HBsAg variants can lead to ER-derived oxidative stress and liver cell death in HuH-7 cells. 展开更多
关键词 Endoplasmic reticulum oxidative stress Hepatitis b virus KD variant COLOCALIZATION Reactive oxidative species Apoptotic cell death
暂未订购
Increased pathogenicity and aerosol transmission for one SARS-CoV-2 B.1.617.2 Delta variant over the wild-type strain in hamsters 被引量:2
13
作者 Xinghai Zhang Shaohong Chen +10 位作者 Zengguo Cao Yanfeng Yao Junping Yu Junhui Zhou Ge Gao Ping He Zhuo Dong Jie Zhong Jing Luo Hongping Wei Huajun Zhang 《Virologica Sinica》 SCIE CAS CSCD 2022年第6期796-803,共8页
During the two-year pandemic of coronavirus disease 2019(COVID-19), its causative agent, severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), has been evolving. SARS-CoV-2 Delta, a variant of concern, has beco... During the two-year pandemic of coronavirus disease 2019(COVID-19), its causative agent, severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), has been evolving. SARS-CoV-2 Delta, a variant of concern, has become the dominant circulating strain worldwide within just a few months. Here, we performed a comprehensive analysis of a new B.1.617.2 Delta strain(Delta630) compared with the early WIV04 strain(WIV04) in vitro and in vivo, in terms of replication, infectivity, pathogenicity, and transmission in hamsters. When inoculated intranasally, Delta630 led to more pronounced weight loss and more severe disease in hamsters. Moreover, 40%mortality occurred about one week after infection with 10^(4)PFU of Delta630, whereas no deaths occurred even after infection with 10^(5)PFU of WIV04 or other strains belonging to the Delta variant. Moreover, Delta630outgrew over WIV04 in the competitive aerosol transmission experiment. Taken together, the Delta630 strain showed increased replication ability, pathogenicity, and transmissibility over WIV04 in hamsters. To our knowledge, this is the first SARS-CoV-2 strain that causes death in a hamster model, which could be an asset for the efficacy evaluation of vaccines and antivirals against infections of SARS-CoV-2 Delta strains. The underlying molecular mechanisms of increased virulence and transmission await further analysis. 展开更多
关键词 SARS-CoV-2 b.1.617.2 Delta variant Syrian hamsters PATHOGENICITY Transmission
原文传递
Nonsense variant of ATP8B1 gene in heterozygosis and benign recurrent intrahepatic cholestasis: A case report and review of literature 被引量:3
14
作者 Mariano Piazzolla Nicola Castellaneta +7 位作者 Antonio Novelli Emanuele Agolini Dario Cocciadiferro Leonardo Resta Loren Duda Michele Barone Enzo Ierardi Alfredo Di Leo 《World Journal of Hepatology》 2020年第2期64-71,共8页
BACKGROUND Benign recurrent intrahepatic cholestasis is a genetic disorder with recurrent cholestatic jaundice due to ATP8B1 and ABCB11 gene mutations encoding for hepato-canalicular transporters.Herein,we firstly pro... BACKGROUND Benign recurrent intrahepatic cholestasis is a genetic disorder with recurrent cholestatic jaundice due to ATP8B1 and ABCB11 gene mutations encoding for hepato-canalicular transporters.Herein,we firstly provide the evidence that a nonsense variant of ATP8B1 gene(c.1558A>T)in heterozygous form is involved in BRIC pathogenesis.CASE SUMMARY A 29-year-old male showed severe jaundice and laboratory tests consistent with intrahepatic cholestasis despite normal gamma-glutamyltranspeptidase.Acute and chronic liver diseases with viral,metabolic and autoimmune etiology were excluded.Normal intra/extra-hepatic bile ducts were demonstrated by magnetic resonance.Liver biopsy showed:Cholestasis in the centrilobular and intermediate zones with bile plugs and intra-hepatocyte pigment,Kupffer’s cell activation/hyperplasia and preserved biliary ducts.Being satisfied benign recurrent intrahepatic cholestasis diagnostic criteria,ATP8B1 and ABCB11 gene analysis was performed.Surprisingly,we found a novel nonsense variant of ATP8B1 gene(c.1558A>T)in heterozygosis.The variant was confirmed by Sanger sequencing following a standard protocol and tested for familial segregation,showing a maternal inheritance.Immunohistochemistry confirmed a significant reduction of mutated gene related protein(familial intrahepatic cholestasis 1).The patient was treated with ursodeoxycholic acid 15 mg/kg per day and colestyramine 8 g daily with total bilirubin decrease and normalization at the 6th and 12th mo.CONCLUSION A genetic abnormality,different from those already known,could be involved in familial intrahepatic cholestatic disorders and/or pro-cholestatic genetic predisposition,thus encouraging further mutation detection in this field. 展开更多
关键词 benign recurrent intrahepatic cholestasis ATP8b1/AbCb11 genes Jaundice Heterozygous variant of ATP8b1 gene(c.1558A>T) Familial inheritance Case report
暂未订购
Expression of ΔDNMT3B Variants and Its Association with Estrogen/Progestogen Receptor Status in Breast Cancer
15
作者 Ning-hong Liu Lu Yang Ming-lei Zhuo Jie Wang Shu-hang Wang Jun Zhao Hua Bai 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2009年第3期229-234,共6页
Objective: Our previous study has showed that △DNMT3B is the predominant form of DNMT3B in non-small cell lung cancer (NSCLC). In this study, we aimed to explore the expression patterns of the △DNMT3B variants in... Objective: Our previous study has showed that △DNMT3B is the predominant form of DNMT3B in non-small cell lung cancer (NSCLC). In this study, we aimed to explore the expression patterns of the △DNMT3B variants in breast cancer and to identify whether the pattern was similar to that in NSCLC or not and its clinical significance. Methods: Expression of seven △DNMT3B variants in 59 breast cancer and the corresponding normal tissue was measured using RT-PCR. The correlations between the expressions of △DNMT3B variants and the clinical parameters including ER/PR status, clincopathologic feature and survivals were analyzed. Results: There were significant differences in the expression ratios of △DNMT3B1-7 variants between breast cancer tissues and normal tissues (P〈0.001). The positive ratio of △DNMT3B1-7 variants were 66%, 71%, 17%, 51%, 76.2%, 50% and 61% in tumor tissue, respectively; while 16%, 8.4%, 3.38%, 3.38%, 11.8%, 13.5% and 5.08% in the corresponding normal tissue, which was different from the pattern of △DNMT3B1-7 expression in NSCLC (62%, 76%, 2.5%, 46%, 18%, 27% and 16% in tumor tissue, respectively; while 18%, 11%, 0%, 3.3%, 0%, 0% and 0% in normal lung tissue, respectively; P〈0.0001). Expressions of △DNMT3B2, 3B4 and 3B7 were higher in the patients with negative estrogen receptor (ER) than those with positive estrogen receptor (P=0.035, P=0.0141 and P=0.0219, respectively). △DNMT3B7 expression was higher for the patients with negative progestogen receptor (PR) compared to those with positive progestogen receptor (P=0.0379). Expression ratio of △DNMT3B5 in stage Ⅲ tumors is lower than that in stage Ⅰ/Ⅱ ones (P= 0.041). But we did not find any relation between the △DNMT3B variants and the patients' survival. Conclusion: The pattern of △DNMT3B variants in breast cancer is different from that in NSCLC. Expressions of △DNMT3B2, 3B4 and 3B7 are associated with estrogen receptors status. While △DNMT3B7 is associated with progestogen receptor. No relation between the △DNMT3B variants and the patients' survival were found. 展开更多
关键词 △DNMT3b variants RT-PCR breast cancer Estrogen receptor Progestogen receptor
在线阅读 下载PDF
Case series in Indonesia:B.1.617.2(delta)variant of SARS-CoV-2 infection after a second dose of vaccine
16
作者 Anis Karuniawati Ari F Syam +5 位作者 Armand Achmadsyah Fera Ibrahim Yulia Rosa Pratiwi Sudarmono Fadilah Fadilah Menaldi Rasmin 《World Journal of Clinical Cases》 SCIE 2022年第36期13216-13226,共11页
BACKGROUND The B.1.617.2(delta)variant of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)was first discovered in Maharashtra in late 2020 and has rapidly expanded across India and worldwide.It took only 2 ... BACKGROUND The B.1.617.2(delta)variant of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)was first discovered in Maharashtra in late 2020 and has rapidly expanded across India and worldwide.It took only 2 mo for this variant to spread in Indonesia,making the country the new epicenter of the delta variant as of July 2021.Despite efforts made by accelerating massive rollouts of current vaccines to protect against infection,cases of fully-vaccinated people infected with the delta variant have been reported.AIM To describe the demographic statistics and clinical presentation of the delta variant infection after the second dose of vaccine in Indonesia.METHODS A retrospective,single-centre case series of the general consecutive population that worked or studied at Faculty of Medicine,Universitas Indonesia with confirmed Delta Variant Infection after a second dose of vaccine from 24 June and 25 June 2021.Cases were collected retrospectively based on a combination of author recall,reverse transcription-polymerase chain reaction(RT-PCR),and whole genome sequencing results from the Clinical Microbiology Laboratory,Faculty of Medicine,Universitas Indonesia.RESULTS Between 24 June and 25 June 2021,15 subjects were confirmed with the B.1.617.2(delta)variant infection after a second dose of the vaccine.Fourteen subjects were vaccinated with CoronaVac(Sinovac)and one subject with ChAdOx1 nCoV-19(Oxford-AstraZeneca).All of the subjects remained in home isolation,with fever being the most common symptom at the onset of illness(n=10,66.67%).The mean duration of symptoms was 7.73 d(±5.444).The mean time that elapsed from the first positive swab to a negative RT-PCR test for SARS-CoV-2 was 17.93 d(±6.3464).The median time that elapsed from the second dose of vaccine to the first positive swab was 87 d(interquartile range:86-128).CONCLUSION Although this case shows that after two doses of vaccine,subjects are still susceptible to the delta variant infection,currently available vaccines remain the most effective protection.They reduce clinical manifestations of COVID-19,decrease recovery time from the first positive swab to negative swab,and lower the probability of hospitalization and mortality rate compared to unvaccinated individuals. 展开更多
关键词 COVID-19/SARS-CoV-2 infection b.1.617.2(delta)variant Fully vaccinated Case series
暂未订购
SARS-CoV-2 Omicron variant (B.1.1.529): A concern with immune escape
17
作者 Adekunle Sanyaolu Aleksandra Marinkovic +5 位作者 Stephanie Prakash Nafees Haider Martina Williams Chuku Okorie Olanrewaju Badaru Stella Smith 《World Journal of Virology》 2022年第3期137-143,共7页
Omicron,the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)variant that is now spreading across the world,is the most altered version to emerge so far,with mutations comparable to changes reported in earli... Omicron,the severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)variant that is now spreading across the world,is the most altered version to emerge so far,with mutations comparable to changes reported in earlier variants of concern linked with increased transmissibility and partial resistance to vaccineinduced immunity.This article provides an overview of the SARS-CoV-2 variant Omicron(B.1.1.529)by reviewing the literature from major scientific databases.Although clear immunological and clinical data are not yet available,we extrapolated from what is known about mutations present in the Omicron variant of SARS-CoV-2 and offer preliminary indications on transmissibility,severity,and immune escape through existing research and databases. 展开更多
关键词 SARS-CoV-2 COVID-19 Omicron b.1.1.529 variant of concern Emerging variants
暂未订购
血清PIVKA-Ⅱ、AFP与spHBV联合检测对HBV所致肝细胞癌的诊断及预后预测价值
18
作者 李英 罗国霞 +3 位作者 幸娟霞 付素容 秦梅 刘婷婷 《中西医结合肝病杂志》 2025年第10期1238-1243,共6页
目的:探究血清异常凝血酶原(PIVKA-Ⅱ)、甲胎蛋白(AFP)与乙型肝炎病毒基因组剪接变异体(spHBV)联合检测对HBV所致肝细胞癌(HBV-HCC)的诊断及预后预测价值。方法:选择2018年3月至2019年5月收治的HBV-HCC患者125例(HBV-HCC组),以及同时期... 目的:探究血清异常凝血酶原(PIVKA-Ⅱ)、甲胎蛋白(AFP)与乙型肝炎病毒基因组剪接变异体(spHBV)联合检测对HBV所致肝细胞癌(HBV-HCC)的诊断及预后预测价值。方法:选择2018年3月至2019年5月收治的HBV-HCC患者125例(HBV-HCC组),以及同时期诊治的单纯HBV患者(HBV组)和HBV所致肝硬化患者(HBV肝硬化组)各125例,检测血清PIVKA-Ⅱ、AFP、spHBV水平。Kaplan-Meier法分析血清PIVKA-Ⅱ、AFP、spHBV水平与HBV-HCC患者预后的关系;COX风险回归分析影响HBV-HCC患者预后的因素;受试者工作特征(ROC)曲线评价血清PIVKA-Ⅱ、AFP、spHBV单独或联合检测对HBV-HCC的诊断和预后预测效能。结果:HBV-HCC组血清PIVKA-Ⅱ、AFP、spHBV水平均高于HBV肝硬化组和HBV组,HBV肝硬化组高于HBV组(P<0.05);死亡患者血清PIVKA-Ⅱ、AFP、spHBV水平均高于生存患者(P>0.05);HBV-HCC患者血清PIVKA-Ⅱ、AFP、spHBV水平与肿瘤数量、TNM分期、肝外是否转移有关(P<0.05);PIVKA-Ⅱ高表达患者36个月生存率低于低表达患者(χ^(2)=6.561,P=0.010),AFP高表达患者36个月生存率低于低表达患者(χ^(2)=4.789,P=0.029),spHBV高表达患者36个月生存率低于低表达患者(χ^(2)=5.761,P=0.016);多因素COX回归分析显示,血清PIVKA-Ⅱ、AFP、spHBV高表达、多个肿瘤、TNM分期为Ⅲ~Ⅳ期、肝外转移均是导致HBV-HCC患者死亡的危险因素(P<0.05);血清PIVKA-Ⅱ、AFP、spHBV联合诊断HBV-HCC的曲线下面积(AUC)显著大于PIVKA-Ⅱ、AFP及spHBV单独诊断的AUC(P<0.05);血清PIVKA-Ⅱ、AFP、spHBV联合预测HBV-HCC患者预后的AUC显著大于三者单独预测的AUC(P<0.05)。结论:血清PIVKA-Ⅱ、AFP与spHBV联合检测对于HBV-HCC的诊断和预后预测具有较高的临床价值。 展开更多
关键词 异常凝血酶原 甲胎蛋白 乙型肝炎病毒基因组剪接变异体 肝癌 预后预测 诊断
暂未订购
胃肠道原发梭形细胞变异型弥漫性大B细胞淋巴瘤4例临床病理学分析
19
作者 曹芳 黎水仙 +3 位作者 郑菲 李葱 李里香 黄文勇 《临床与实验病理学杂志》 北大核心 2025年第8期1077-1081,共5页
目的探讨胃肠道原发梭形细胞变异型弥漫性大B细胞淋巴瘤(spindle cell variant of diffuse large B-cell lymphoma,SV-DLBCL)的临床病理特点、诊断与鉴别诊断。方法收集4例胃肠道原发SV-DLBCL临床资料,行免疫组化染色及EBER原位杂交检测... 目的探讨胃肠道原发梭形细胞变异型弥漫性大B细胞淋巴瘤(spindle cell variant of diffuse large B-cell lymphoma,SV-DLBCL)的临床病理特点、诊断与鉴别诊断。方法收集4例胃肠道原发SV-DLBCL临床资料,行免疫组化染色及EBER原位杂交检测,并结合相关文献分析其临床病理学特征。结果4例患者年龄49~91岁,发生于胃1例,小肠2例,结肠1例。临床表现以腹痛及肠梗阻症状为主。镜下示肿瘤细胞呈弥漫性分布,主要由梭形细胞构成,被胶原束分隔成条索状,细胞中等偏大、可见核仁,核分裂易见。免疫表型:肿瘤细胞表达CD20、PAX5等B细胞标志物,4例中3例为non-GCB型、1例为GCB型,CD30和原位杂交EBER均阴性,Ki67增殖指数均>80%。FISH检测结果显示其中1例BCL6基因断裂信号阳性,其他3例均阴性;4例MYC基因和BCL2基因断裂信号均阴性。结论胃肠道原发的SV-DLBCL较为罕见,需与胃肠道发生的其他梭形细胞肿瘤相鉴别,诊断时需结合HE形态及免疫组化标记等综合判断。 展开更多
关键词 胃肠道肿瘤 淋巴瘤 梭形细胞变异型弥漫性大b细胞淋巴瘤 临床病理特点 鉴别诊断
暂未订购
血清UHRF2、FDP和spHBV联合检测在HBV相关性肝细胞癌诊断及预后预测中的价值
20
作者 王晶晶 张维伦 +1 位作者 王超 李伟安 《国际消化病杂志》 2025年第5期343-349,共7页
目的探究血清泛素样含PHD和环指域蛋白2(UHRF2)、纤维蛋白原降解产物(FDP)和HBV基因组剪接变异体(spHBV)联合检测在HBV相关性肝细胞癌(HCC)诊断及预后预测中的价值。方法选择2019年9月至2020年10月佳木斯市中心医院收治的80例HBV相关性... 目的探究血清泛素样含PHD和环指域蛋白2(UHRF2)、纤维蛋白原降解产物(FDP)和HBV基因组剪接变异体(spHBV)联合检测在HBV相关性肝细胞癌(HCC)诊断及预后预测中的价值。方法选择2019年9月至2020年10月佳木斯市中心医院收治的80例HBV相关性HCC患者(设为HBV-HCC组)、80例单纯HBV患者(设为单纯HBV组)和80例HBV所致肝硬化患者(设为HBV肝硬化组)作为研究对象。采用ELISA法检测血清UHRF2、FDP表达水平。采用实时荧光定量PCR法检测血清spHBV表达水平。采用ROC曲线分析血清UHRF2、FDP和spHBV对HBV相关性HCC的诊断及预后预测价值。采用Kaplan-Meier生存曲线分析血清UHRF2、FDP和spHBV与HBV相关性HCC患者预后的关系。采用单因素和多因素Cox比例风险回归模型分析HBV相关性HCC患者预后的危险因素。结果HBV-HCC组、HBV肝硬化组和单纯HBV组的血清UHRF2、FDP和spHBV表达水平均依次降低(P均<0.05)。ROC曲线分析结果显示,血清UHRF2、FDP和spHBV联合检测诊断HBV相关性HCC的AUC分别大于UHRF2(Z=2.590,P=0.010)、FDP(Z=2.906,P=0.004)和spHBV(Z=2.734,P=0.006)单独检测。随访结果显示,死亡组的血清UHRF2、FDP和spHBV表达水平均显著高于生存组(P均<0.05)。Kaplan-Meier生存曲线分析结果显示,UHRF2高表达组、FDP高表达组和spHBV高表达组的3年生存率分别低于UHRF2低表达组、FDP低表达组和spHBV低表达组,差异均有统计学意义(P均<0.05)。ROC曲线分析结果显示,血清UHRF2、FDP和spHBV联合检测预测HBV相关性HCC患者预后的AUC分别大于UHRF2(Z=2.013,P=0.048)、FDP(Z=2.113,P=0.032)和spHBV(Z=2.016,P=0.046)单独检测。多因素Cox回归分析结果显示,血清UHRF2、FDP和spHBV高表达均是HBV相关性HCC患者随访3年内死亡的独立危险因素(P均<0.05)。结论血清UHRF2、FDP和spHBV联合检测对HBV相关性HCC患者的诊断及预后预测均具有较高的临床价值。 展开更多
关键词 HbV 肝细胞癌 泛素样含PHD和环指域蛋白2 纤维蛋白原降解产物 HbV基因组剪接变异体 预后 诊断
暂未订购
上一页 1 2 7 下一页 到第
使用帮助 返回顶部